The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients

Quality of Life Research

Volumn 24, Issue 7, 2015, Pages 1767-1774

  Pan, Chen Wei ^a   Sun, Hong Peng ^a   Wang, Xingzhi ^b   Ma, Qinghua ^c   Xu, Yong ^a   Luo, Nan ^b   Wang, Pei ^b  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Suzhou Xiangcheng People's Hospital   (China)

Author keywords

China; Diabetes; Discriminative power; EQ 5D 3L; EQ 5D 5L; Preference

Indexed keywords

ADULT; CHINA; DEPRESSION; FEMALE; HEALTH STATUS; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PSYCHOLOGY; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; REPRODUCIBILITY; SELF CARE;

ADULT; CHINA; DEPRESSION; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PAIN; PSYCHOMETRICS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SELF CARE; SURVEYS AND QUESTIONNAIRES;

EID: 84933279105     PISSN: 09629343     EISSN: 15732649     Source Type: Journal    
DOI: 10.1007/s11136-014-0902-6     Document Type: Article

References (35)

1. Rabin, R., & de Charro, F. (2001). EQ-5D: A measure of health status from the EuroQol Group. Annals of Medicine,33, 337–343.
2. Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care,35, 1095–1108.
3. Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: Development and testing of the D1 valuation model. Medical Care,45, 203–220.
4. Liu, G., Wu, H., Li, M., Gao, C., & Luo, N. (2014). Chinese time trade-off values for EQ-5D health states. Value in Health,17, 597–604.
5. Luo, N., Wang, P., Thumboo, J., Lim, Y. W., & Vrijhoef, H. J. (2014). Valuation of EQ-5D-3L health states in Singapore: Modeling of time trade-off values for 80 empirically observed health states. Pharmacoeconomics,30(5), 495–507.
6. Tsuchiya, A., Ikeda, S., Ikegami, N., Nishimura, S., Sakai, I., Fukuda, T., et al. (2002). Estimating an EQ-5D population value set: The case of Japan. Health Economics,11(4), 341–353.
7. Baida, X., Roset, M., Herdman, M., & Kind, P. (2001). A comparison of United Kingdom and Spanish general population general population time trade-off values for EQ-5D health states. Medical Decision Making,21(1), 7–16.
8. Luo, N., Johnson, J. A., Shaw, J. W., & Coons, S. J. (2007). A comparison of EQ-5D index scores derived from the US and UK population-based scoring functions. Medical Decision Making,27(3), 321–326.
9. Norman, R., Cronin, P., Viney, R., King, M., Street, D., & Ratcliffe, J. (2009). International comparisons in valuing EQ-5D health states: A review and analysis. Value in Health,12(8), 1194–1200.
10. Janssen, M. F., Lubetkin, E. I., Sekhobo, J. P., & Pickard, A. S. (2011). The use of the EQ-5D preference-based health status measure in adults with Type 2 diabetes mellitus. Diabetic Medicine,28, 395–413.
11. Wang, H. M., Patrick, D. L., Edwards, T. C., Skalicky, A. M., Zeng, H. Y., & GU, W. W. (2012). Validation of the EQ-5D in a general population sample in urban China. Quality of Life Research,21(1), 155–160.
12. Luo, N., Cang, S. Q., Quan, H. M. J., How, C. H., & Tay, E. G. (2012). The discriminative power of the EuroQol visual analog scale is sensitive to survey language in Singapore. Health and Quality of Life Outcomes,10, 32.
13. Pickard, A. S., Wilke, C. T., Lin, H. W., et al. (2007). Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics,25, 365–394.
14. Ong, S. C., Mark, B., Aung, M. O., Li, S. C., & Lim, S. G. (2008). Health-related quality of life in chronic hepatitis B patients. Hepatology,47(4), 1108–1117.
15. McLernon, D. J., Dillon, J., & Donna, P. T. (2008). Health-state utilities in liver disease: A systematic review. Medical Decision Making,28(4), 582–592.
16. Macran, S., Weatherly, H., & Kind, P. (2003). Measuring population health? A comparison of three generic health status measures. Medical Care,42, 218–231.
17. Petrou, S., & Hockely, C. (2005). An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Economics,14, 1169–1189.
18. Myers, C., & Wilks, D. (1999). Comparison of Euroqol EQ-5D and SF-36 in patients with chronic fatigue syndrome. Quality of Life Research,8, 9–16.
19. Bharmal, M., & Thomas, J. I. I. I. (2006). Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value in Health,9, 262–271.
20. Wang, H., Kindig, D. A., & Mullahy, J. (2005). Variation in Chinese population health related quality of life: Results from a EuroQol study in Beijing, China. Quality of Life Research,14, 119–132.
21. Brazier, J., Roberts, J., & Tsychiya, A. (2004). A comparison of the EQ-5D and SF-6D across seven patients groups. Health Economics,13, 873–884.
22. Bech, P., Moses, R., & Gomis, R. (2008). The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naïve Type 2 diabetes: A placebo-controlled, multicentre study. Quality of Life Research,12, 413–425.
23. Bagust, A., & Beale, S. (2005). Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Economics,14, 217–230.
24. Morgan, C. L., McEwan, P., Morrissey, M., Peter, J. R., Poole, C., & Currie, C. J. (2006). Characterization and comparison of health-related utility in people with diabetes with various single and multiple vascular complications. Diabetic Medicine,23, 1100–1105.
25. EuroQol Group. EQ-5D-5L User Guide. (2014). Basic information on how to use the EQ-5D-5L instrument. http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/UserGuide_EQ-5D-5L.pdf. Accessed 10 July 2014.
26. van Hout, B., Janssen, M. F., Feng, Y. S., Kohlmann, T., Busschbach, J., Golicki, D., et al. (2012). Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value in Health,15(5), 708–715.
27. Jia, Y. X., Cui, F. Q., Li, L., Zhang, D. L., Zhang, G. M., Wang, F. Z., et al. (2014). Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. Quality of Life Research,. doi:10.1007/311136-014-0670-3.
28. Kim, S. H., Kim, H. J., Lee, S. I., & Jo, M. W. (2012). Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea. Quality of Life Research,21(6), 1065–1073.
29. Pickard, A. S., De leon, M. C., Kohlmann, T., Cella, D., & Rosenbloom, S. (2007). Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Medical Care,45(3), 259–263.
30. Scalone, L., Ciampichini, R., Fagiuoli, S., Gardini, I., Fusco, F., Gaeta, L., et al. (2013). Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic disease. Quality of Life Research,22(7), 1707–1716.
31. Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., et al. (2013). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: A multi-country study. Quality of Life Research,22(7), 1717–1727.
32. Janssen, M. F., Birnie, E., Haagsma, J. A., & Bonsel, G. J. (2008). Comparing the standard EQ-5D three-level system with a five-level version. Value in Health,11(2), 275–284.
33. Craig, B. M., Pickard, A. S., & Lubetkin, E. I. (2014). Health problems are more common, but less severe when measured using newer EQ-5D versions. Journal of Clinical Epidemiology,67, 93–99.
34. Shannon, C. E., & Weaver, W. (1948). A mathematical theory of communication. Bell System Technical Journal,27, 161–163.
35. Janssen, M. F., Birnie, E., & Bonsel, G. J. (2007). Evaluating the discriminatory power of EQ-5D, HUI2 and HUI3 in a US general population survey using Shannon’s indices. Quality of Life Research,16(5), 895–904.